THL – TorHoerman Law

Xarelto

The ease of using new oral anticoagulants like Xarelto and Pradaxa have made them big sellers as they take over the market for the old standard warfarin. But, patients prescribed Xarelto and these other new oral anticoagulants need to understand that taking these drugs comes with a risk that does not exist with warfarin – there is currently no antidote to stop the bleeding.

According to the Institute for Safe Medicine Practices (ISMP), a watchdog group, anticoagulant drugs are a “high-risk treatment” and cause bleeding in approximately 15% of patients with atrial fibrillation. Many physicians are wary of the new anticoagulants since there is limited evidence on how to manage bleeding in patients taking them since there is no known reversal of the anticoagulant effect.

The lack of a specific antidote was one factor that led to over 4,000 lawsuits being filed against Boehringer Ingelheim, the maker of Pradaxa who recently agreed to pay $650 million to settle these lawsuits. Lawyers speaking to people injured by Xarelto believe that Bayer and J&J may also find themselves defending Xarelto for similar injuries as Xarelto is now the top prescribed anticoagulant in the U.S.

If you or a loved one bled after taking Xarelto and it led to serious or fatal injuries, THL would like to discuss legal options with you.

Tor Hoerman was a co-lead attorney in the Pradaxa litigation that resulted in the settlement of $650 million to individuals injured as a result of their Pradaxa use. THL is currently talking to individuals that believe Xarelto may be to blame for their serious injuries that resulted when they were unable to stop a bleed.

THL is a national drug, medical device and toxic tort law firm representing clients in 50 states. We are not afraid to take on the largest companies when they put profits ahead of safety.

 

Xarelto Updates:

May 3, 2017 – In the first of four bellwether trials, a jury ruled in favor of the defense rejecting the plaintiff’s claim that the defendant’s had failed to notify the plaintiff’s doctor of the risks associated with Xarelto. More than 18,000 plaintiffs allege that Xarelto, an anticoagulant, caused them to suffer from uncontrollable bleeding.

June 12, 2017 – A New Orleans jury ruled in favor of Xarelto manufacturers in the second bellwether trial in the multidistrict litigation.

August 18, 2017 – In the third bellwether trial, a jury once again ruled in favor of Xarelto’s manufacturers, Janssen Pharmaceuticals Inc. and Bayer.

December 5, 2017 – In a groundbreaking decision, a Pennsylvania jury awarded $29 M to a plaintiff who claimed that Xarelto manufacturers failed to warn consumers of the adverse health risks associated with the blood thinner medication.

+ - References

Thomas J Moore, Michael R Cohen, Curt D Furberg. “Perspective on Drug Hypersensitivity.”QuarterWatch: Monitoring FDA MedWatch Reports, www.ismp.org/quarterwatch/pdfs/2013Q1.pdf.

No-Obligation Free Consultation

Contact us by phone at (618) 656-4400 or email us below.

Sidebar Contact

Your information will be used only so that we may contact you to evaluate your case. Your contact information will never be shared or sold to anyone other than TorHoerman Law.